Cedar Hill Associates’s iShares Biotechnology ETF IBB Stock Holding History

Cedar Hill Associates’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$3.35M	Sell	34,770 -21,667	-38%	-$2.3M	1.28%	28
2018 Q3	$6.88M	Sell	56,437 -5,729	-9%	-$675K	1.55%	23
2018 Q2	$6.83M	Sell	62,166 -5,645	-8%	-$604K	1.42%	25
2018 Q1	$7.24M	Sell	67,811 -7,402	-10%	-$820K	1.44%	28
2017 Q4	$8.03M	Sell	75,213 -54,663	-42%	-$5.84M	1.4%	28
2017 Q3	$14.4M	Sell	129,876 -891	-0.7%	-$95.2K	2.49%	5
2017 Q2	$13.5M	Sell	130,767 -4,080	-3%	-$402K	2.81%	9
2017 Q1	$13.2M	Sell	134,847 -52,089	-28%	-$4.99M	2.75%	12
2016 Q4	$16.5M	Sell	186,936 -1,845	-1%	-$168K	2.78%	12
2016 Q3	$18.2M	Buy	188,781 +15,609	+9%	+$1.48M	2.98%	7
2016 Q2	$14.9M	Buy	173,172 +5,565	+3%	+$499K	2.55%	16
2016 Q1	$14.6M	Buy	167,607 +10,980	+7%	+$982K	2.53%	17
2015 Q4	$17.7M	Buy	156,627 +59,163	+61%	+$6.42M	3.11%	6
2015 Q3	$9.86M	Sell	97,464 -58,464	-37%	-$7.01M	1.75%	28
2015 Q2	$19.2M	Sell	155,928 -1,422	-0.9%	-$170K	3.02%	6
2015 Q1	$18M	Buy	157,350 +56,415	+56%	+$6.22M	2.86%	6
2014 Q4	$10.2M	Buy	+100,935	New	+$9.81M	1.61%	28

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Cedar Hill Associates's IBB Position: Q4 2018 in Review

Cedar Hill Associates reduced its iShares Biotechnology ETF (IBB) stake by 38% in Q4 2018, selling an estimated $2.3M and leaving 34,770 shares worth $3.35M. The position accounts for 1.28% of the portfolio, ranked #28.

Cedar Hill Associates first reported a position in IBB in Q4 2014 and has held it in 17 quarters since. The position peaked at $19.2M in Q2 2015. 649 funds tracked by Wall St. Rank hold IBB as of Q4 2018.

Cedar Hill Associates held 34,770 shares of iShares Biotechnology ETF worth $3.35M as of Q4 2018.
Cedar Hill Associates sold 21,667 iShares Biotechnology ETF shares in Q4 2018, an estimated $2.3M.
iShares Biotechnology ETF made up 1.28% of Cedar Hill Associates's portfolio in Q4 2018, its #28 holding.
Cedar Hill Associates first reported a position in iShares Biotechnology ETF in Q4 2014 and has held it in 17 quarters since.
Cedar Hill Associates's iShares Biotechnology ETF position peaked at $19.2M in Q2 2015.
649 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2018.

Based on Cedar Hill Associates's 13F filing for Q4 2018, filed 13 Feb 2019.